23h
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
Eli Lilly and Co. (NYSE:LLY) has seen better days. The stock is up 26.04% for the last year but has struggled recently, ...
Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an ...
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
The Motley Fool on MSN4d
Is It Time to Sell Eli Lilly and Pfizer Stocks?Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid. Eli Lilly now ranks as the largest drugmaker in the ...
On November 20, Gabrielle Sulzberger, Director at Eli Lilly LLY executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: In a significant move reported in a Form 4 ...
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.
Conditions are getting a bit more challenging for the drugmaker.
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback